Banque Transatlantique SA Buys 17,201 Shares of Johnson & Johnson $JNJ

Key Points

• Banque Transatlantique SA increased its stake in Johnson & Johnson by 19.4%, now holding 105,783 shares valued at approximately $16.2 million.
• Johnson & Johnson recently reported earnings of $2.77 EPS, exceeding estimates, with quarterly revenue at $23.74 billion, a 5.8% increase from the previous year.
• The company announced a quarterly dividend of $1.30 per share, with an annualized yield of 2.9%, reflecting a payout ratio of 55.61%.

Banque Transatlantique SA increased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 19.4% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 105,783 shares of the company's stock after acquiring an additional 17,201 shares during the quarter. Banque Transatlantique SA's holdings in Johnson & Johnson were worth $16,212,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of JNJ. Elios Financial Group Inc. lifted its position in Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock valued at $746,000 after buying an additional 66 shares during the period. Atlantic Family Wealth LLC lifted its position in Johnson & Johnson by 4.4% during the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after buying an additional 67 shares during the period. MBA Advisors LLC lifted its position in Johnson & Johnson by 1.2% during the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after buying an additional 68 shares during the period. Sovereign Financial Group Inc. lifted its position in Johnson & Johnson by 1.8% during the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after buying an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc lifted its position in Johnson & Johnson by 1.5% during the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock valued at $767,000 after buying an additional 69 shares during the period. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the company. Guggenheim reissued a "neutral" rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Bank of America lifted their price target on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Wall Street Zen lowered Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Morgan Stanley lifted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Finally, Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus target price of $176.29.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded down $0.57 during trading hours on Friday, reaching $178.20. 9,733,095 shares of the stock traded hands, compared to its average volume of 7,556,979. The company has a 50 day moving average price of $168.06 and a 200 day moving average price of $160.60. The firm has a market capitalization of $429.15 billion, a price-to-earnings ratio of 19.06, a P/E/G ratio of 2.28 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.